Real-World Impact of Deucravacitinib in Psoriasis Care

Deucravacitinib, a selective TYK2 inhibitor approved for moderate-to-severe plaque psoriasis (PsO), has already demonstrated robust efficacy in phase three trials. But how well do those results translate to real-world clinical practice? A new prospective cohort study presented at the 2025 Winter Clinical Dermatology Conference offers compelling evidence that patients who persist on deucravacitinib experience clinically meaningful improvements in symptoms, quality of life, and treatment satisfaction over six months. Here’s a quick look at the study and its findings.

Study Overview

Researchers followed 306 U.S. adults who initiated deucravacitinib within two weeks of study enrollment, capturing outcomes via the FORWARD registry and a national dermatology network. Of those, 81 completed six-month follow-up, and 51 (63 percent) were persistent on therapy—forming the primary analysis cohort.

All outcomes were patient-reported, including:

• Psoriasis Symptoms and Signs Diary (PSSD)
• Dermatology Life Quality Index (DLQI)
• Itch and nail disease severity (numeric rating scales)
• Patient-Reported Extent of Psoriasis Involvement (PREPI), a proxy for body surface area (BSA) affected
• Treatment satisfaction on a 5-Point Likert scale

Key Results

Looking at the results, among patients persistent on treatment at six months:

• PSSD scores improved by 19 points, reflecting signficant symptom reduction.
• DLQI improved by 4.3 points, signifying a transition from moderate to mild life impact.
• Itch and global PsO assessments also improved significantly.
• BSA involvement decreased notably: the proportion of patients reporting less than or equal to two percent involvement rose from 45 to over 86 percent by six months.

Treatment Satisfaction by Patient Report

Patients who persisted on treatment reported higher rates of satisfaction. The study found that at baseline, only 33.3 percent of patients reported being satisfied or highly satisfied with treatment. By month six that number jumped to 69 percent, with dissatisfaction markedly reduced from 24.5 percent to 5.9 percent.

Study Limitations

As with all real-world registries, selection bias remains a concern—only 26.5 percent of initial patients completed six-month follow-up, and results are limited to those persistent on therapy.

Clinical Takeaways

These results are particularly meaningful given the challenges of maintaining patient adherence and satisfaction in chronic dermatologic care. Deucravacitinib’s oral administration, tolerable safety profile, and durable real-world efficacy make it a systemic treatment option for patients seeking alternatives to biologics or injectable therapies.

Reference:

1. Ogdie A, Lonowski S, N’Dri L, Khaychuk V, Schumacher R, Michaud K. Impact of deucravacitinib on psoriasis severity and overall patient-reported outcomes in a US prospective cohort study. Presented at the Winter Clinical Dermatology Conference – Hawaii; February 14–19, 2025; Waikoloa, HI.